Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
18.18
+0.30 (1.68%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Innoviva Revenue
In the year 2024, Innoviva had annual revenue of $358.71M with 15.54% growth. Innoviva had revenue of $91.81M in the quarter ending December 31, 2024, with 6.95% growth.
Revenue (ttm)
$358.71M
Revenue Growth
+15.54%
P/S Ratio
3.13
Revenue / Employee
$2,824,496
Employees
127
Market Cap
1.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 358.71M | 48.25M | 15.54% |
| Dec 31, 2023 | 310.46M | -20.88M | -6.30% |
| Dec 31, 2022 | 331.34M | -60.53M | -15.45% |
| Dec 31, 2021 | 391.87M | 55.07M | 16.35% |
| Dec 31, 2020 | 336.79M | 75.78M | 29.03% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
INVA News
- 15 days ago - Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 23 days ago - Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference - Business Wire
- 4 weeks ago - Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress - Business Wire
- 4 weeks ago - Innoviva: Underappreciated Strength In Hospital Therapeutics - Seeking Alpha
- 7 weeks ago - Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 3 months ago - Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole) - Business Wire
- 3 months ago - Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States - GlobeNewsWire
- 4 months ago - Innoviva to Participate in the Citi 2024 Global Healthcare Conference - Business Wire